What is Leerink Partnrs' Estimate for SAGE Q3 Earnings?

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Leerink Partnrs issued their Q3 2025 earnings per share estimates for Sage Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst M. Goodman expects that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter. The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics' FY2025 earnings at ($3.15) EPS, FY2026 earnings at ($1.75) EPS, FY2027 earnings at ($1.95) EPS, FY2028 earnings at ($1.55) EPS and FY2029 earnings at ($1.35) EPS.

Several other equities research analysts also recently commented on the company. TD Cowen reduced their price objective on Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating for the company in a report on Thursday, November 21st. HC Wainwright reiterated a "neutral" rating and issued a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Canaccord Genuity Group reduced their price objective on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a report on Wednesday, February 12th. Wedbush reiterated a "neutral" rating and issued a $6.00 price objective on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $9.65.

Sage Therapeutics Stock Up 0.6 %

Shares of NASDAQ:SAGE traded up $0.04 on Friday, hitting $7.18. 1,993,826 shares of the company traded hands, compared to its average volume of 2,430,069. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $23.22. The stock has a 50 day simple moving average of $6.43 and a 200-day simple moving average of $6.83. The company has a market cap of $439.20 million, a PE ratio of -1.29 and a beta of 0.94.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SAGE. Creative Planning purchased a new position in shares of Sage Therapeutics during the 3rd quarter valued at $88,000. Assenagon Asset Management S.A. lifted its stake in shares of Sage Therapeutics by 11.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 18,814 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company's stock valued at $85,000 after buying an additional 4,672 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of Sage Therapeutics by 21.7% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 45,738 shares of the biopharmaceutical company's stock valued at $330,000 after buying an additional 8,166 shares in the last quarter. Finally, Quest Partners LLC lifted its stake in shares of Sage Therapeutics by 56.3% during the 3rd quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company's stock valued at $133,000 after buying an additional 6,618 shares in the last quarter. Hedge funds and other institutional investors own 99.22% of the company's stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.